Clinical trials: Renal Tumors
Carcinoma, Renal Cell
Safety And Effectiveness Of Daily Dosing With 37.5 mg Sunitinib Malate In Patients With Advanced Kidney Cancer
A phase II study to allow patients with advanced kidney cancer access to sunitinib malate treatment and to find out the good and bad effects of taking 37.5 mg sunitinib malate in a continuous daily regimen (once per day) for one…
- Trial name
- NCT00338884
- Testing
- Sunitinib malate
- Where
- 15 sites in Argentina, Australia and 4 more
- Volunteers
- 120 people
- Sponsor
- Pfizer
Kidney Cancer, Bladder Cancer
A Study of a Side Effects and Resource Navigation Program for People With Cancer
The purpose of this study is to find out if the navigation program helps participants manage immunotherapy treatment better than usual care.
- Conditions
- Kidney Cancer, Bladder Cancer, Breast Cancer, Lung Cancer
- Trial name
- NCT07646847
- Testing
- Immunotherapy CARE Program
- Where
- 8 sites in United States
- Volunteers
- 200 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of ixabepilone in treating young…
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer
- Trial name
- NCT00030108
- Testing
- ixabepilone
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Carcinoma, Renal Cell
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
The goal of this study is to evaluate the efficacy and safety of pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib as first-line treatment in…
- Trial name
- NCT04736706
- Testing
- Pembrolizumab, Belzutifan, Pembrolizumab/Quavonlimab
- Where
- 262 sites in United States, Australia and 33 more
- Volunteers
- 1,688 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC)
SLM + Axitinib for Clear Cell RCC
This phase I trial studies the side effects and best dose of L-selenomethionine when given together with axitinib in treating patients with clear cell renal cell carcinoma that has spread from the primary site (place where it…
- Trial name
- NCT02535533
- Testing
- Selenomethionine (SLM), Axitinib
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Mohammed Milhem
Ewing's Sarcoma, Osteosarcoma
Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors
The best treatment for recurrent cancers or those that do not respond to therapies is not known. Typically, patients with these cancers receive a combination of cancer drugs (chemotherapy), surgery, or radiation therapy.
- Conditions
- Ewing's Sarcoma, Osteosarcoma, Astrocytoma, Atypical Teratoid/Rhabdoid Tumor
- Trial name
- Aflac ST0901 (NCT01331135)
- Testing
- sirolimus
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Emory University
Cancer, End Stage Renal Disease
The Singapore Chinese Health Study
The "Singapore Chinese Health Study" is a cohort study established by the Department of Epidemiology and Public Health in National University of Singapore, together with collaborators from several universities in the United…
- Conditions
- Cancer, End Stage Renal Disease, Diabetes, Cardiovascular Diseases
- Trial name
- SCHS (NCT03356340)
- Volunteers
- 63,257 people, healthy volunteers welcome
- Sponsor
- Duke-NUS Graduate Medical School
Liver Failure, Kidney Failure
Mesenchymal Stem Cells After Renal or Liver Transplantation
The immune system of a patient can attack the liver or the kidney received from a donor (organ rejection). This can be prevented by treating these patients long-life with immunosuppressive drugs.
- Trial name
- NCT01429038
- Testing
- Mesenchymal Stem Cells
- Where
- Belgium
- Volunteers
- 40 people
- Sponsor
- University of Liege
Metastatic Renal Cell Carcinoma
Matched Unrelated Donor Transplant for Metastatic Renal Cell Carcinoma
The purpose of this study is to find out what effects (good and bad) a stem cell transplant from an unrelated donor will have for patients with kidney cancer that has spread to other parts of the body (metastasized).
- Trial name
- NCT00318110
- Testing
- NST using MUD for metastatic renal cell carcinoma
- Where
- 5 sites in United States
- Volunteers
- 4 people
- Sponsor
- Center for International Blood and Marrow Transplant Research
Metastatic Melanoma, Renal Cell Cancer
Mechanism of Action of High-Dose IL-2 (Aldesleukin) in Metastatic Melanoma and Kidney Cancer
Background: -Although IL-2 can shrink tumors in about 20 percent of patients with metastatic kidney cancer and in 15 percent of patients with metastatic melanoma, it is not fully known how the drug works.
- Trial name
- NCT00304460
- Testing
- aldesleukin
- Where
- United States
- Volunteers
- 138 people
- Sponsor
- National Cancer Institute (NCI)
Kidney Cancer, Melanoma (Skin)
Genistein and Interleukin-2 in Treating Patients With Metastatic Melanoma or Kidney Cancer
RATIONALE: Genistein may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00276835
- Testing
- High-dose interleukin-2, genistein
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Northwestern University
Hematologic Diseases, Oncology Problem
Clinical Validation of a Dried Blood Spot Method for Analysis of Immunosuppressives and Antifungals in Pediatrics
This is a clincial validation study of a dried blood spot (DBS) method for the analysis of immunosuppressive and antifungal agents currently subject of therapeutic drug monitoring (TDM) in a pediatric population.
- Conditions
- Hematologic Diseases, Oncology Problem, Kidney Diseases, Transplantation Infection
- Trial name
- PROTECT (NCT02329808)
- Testing
- blood drawing
- Where
- Netherlands
- Volunteers
- 93 people
- Sponsor
- Radboud University Medical Center
Melanoma, Non-small Cell Lung Cancer
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
This is a study to determine the maximum tolerated dose (MTD) for CDX-1140 (CD40 antibody), either alone or in combination with CDX-301 (FLT3L), pembrolizumab, or chemotherapy and to further evaluate its tolerability and efficacy…
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer
- Trial name
- NCT03329950
- Testing
- CDX-1140, CDX-301, pembrolizumab
- Where
- 11 sites in United States
- Volunteers
- 132 people
- Sponsor
- Celldex Therapeutics
Colorectal Adenocarcinoma, Hepatic Carcinoma
Exhaustive Genetic and Immunological Characterization of Colon, Kidney and Liver Tumors
Over the last 10 years, technological advances in molecular biology enabled a more accurate genomic characterization of tumors. For each tumor location, this led to the identification of subgroups with similar molecular…
- Conditions
- Colorectal Adenocarcinoma, Hepatic Carcinoma, Kidney Adenocarcinoma
- Trial name
- ExhauCRF (NCT03149523)
- Where
- 3 sites in France
- Volunteers
- 150 people
- Sponsor
- European Georges Pompidou Hospital
Renal Cell Carcinoma
Dynamic Contrast Enhancement Computed Tomography for Evaluating Tumor Perfusion in Patients With Metastatic Renal Cell Carcinoma Receiving Targeted Therapies: Renal Cell Carcinoma (RCC) Scramble
This is a companion protocol to MD Anderson Cancer Center study 2010-0085 (Sequential Therapy in Advanced Renal Cell Carcinoma Therapy: The "START" Trial).
- Trial name
- NCT01224288
- Testing
- Perfusion CT scan
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- M.D. Anderson Cancer Center
Kidney Cancer
Chemotherapy in Treating Patients With Advanced Kidney Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of fenretinide in treating patients who have advanced…
- Trial name
- NCT00011973
- Testing
- fenretinide
- Where
- 4 sites in United States
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Prostate Cancer, Bladder Cancer
Decipher Genomics Resource for Intelligent Discovery
To prospectively evaluate the utility of genomic expression data and whole slide digital pathology image data as a tool to better characterize the tumors of individual patients, and to understand how genomic and histologic…
- Conditions
- Prostate Cancer, Bladder Cancer, Renal Cancer
- Trial name
- GRID® (NCT02609269)
- Testing
- Decipher Cancer Classifier
- Volunteers
- 1,000,000 people
- Sponsor
- GenomeDx Biosciences Corp
Renal Tumors
Development of AI Model for Renal Tumor Diagnosis Using CT and Lab Tests
This multi-center retrospective study aims to develop a multimodal artificial intelligence diagnostic model using preoperative contrast-enhanced CT images and routine laboratory parameters from patients with renal tumors.
- Trial name
- NCT06761742
- Where
- China
- Volunteers
- 1,922 people
- Sponsor
- RenJi Hospital
Renal Cell Carcinoma
Neoadjuvant Therapy of Pembrolizumab Plus Lenvatinib in Advanced RCC
This is a phase II study to determine the efficacy and safety of Pembrolizumab when given in combination with Lenvatinib as treatment for patients with the advanced kidney cancer.
- Trial name
- NCT05485896
- Testing
- Pembrolizumab plus Lenvatinib
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Tianjin Medical University Second Hospital
Renal Impairment
A Pharmacokinetic Study of YM178 in Normal Subjects and Those With Mild, Moderate, and Severe Renal Impairment
The objective of this study is to assess and compare the pharmacokinetic properties of YM178 in normal subjects and those with mild, moderate and severe renal impairment.
- Trial name
- NCT00750620
- Testing
- YM178
- Where
- 2 sites in United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.